Last-Resort leukemia drug made available to 29 patients
NCT ID NCT07517315
First seen Apr 09, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This program provides continued access to the experimental drug vodobatinib for people with Philadelphia chromosome-positive chronic myeloid leukemia (CML) whose cancer did not respond to previous treatments. It is for patients who were already in the main study and still benefit from the drug, with no other options left. The main study was stopped early due to changes in the treatment landscape, not safety concerns. Patients receive the drug under their doctor's care, and 29 people have transitioned to this expanded access so far.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CML, RELAPSED are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Colentina Clinical Hospital
Bucharest, Romania
-
Georgia Cancer Center at Augusta University
Augusta, Georgia, 30912, United States
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
IRCCS Romagnolo Institute for the Study of Tumors "Dino Amadori"
Meldola, FC, 47014, Italy
-
Léon Bérard Center
Lyon, 69373, France
-
Meenakshi Mission Hospital and Research Centre
Madurai, India
-
Oncology Institute "Prof. Dr. Ion Chiricuță"
Cluj-Napoca, Romania
-
Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer
Navi Mumbai, India
-
University of Debrecen, Clinical Center Institute of Internal Medicine
Debrecen, 4032, Hungary
-
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.